Molecular markers of tumor progression in melanoma

Current Genomics

Volumn 10, Issue 4, 2009, Pages 231-239

  Rother, Joshua ^a   Jones, Dan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alkylating agents; Cell cycle; Genetic progression; Melanoma; Mitotic spindle poisons; Mitotic spindle; Tumor suppressors

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; CARMUSTINE; CHECKPOINT KINASE 1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GROWTH FACTOR; INTERLEUKIN 2; LOMUSTINE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MICROTUBULE ASSOCIATED PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KIT; PROTEIN NRAS; PROTEIN P16; PROTEIN P27; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURGERY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL HETEROGENEITY; CHROMOSOMAL INSTABILITY; DNA REPAIR; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC MODEL; HUMAN; MELANOMA; PATIENT SELECTION; POINT MUTATION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 68749110795     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920209788488526     Document Type: Review

References (83)

1. Rulyak, S.J.; Brentnall, T.A.; Lynch, H.T.; Austin, M.A. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer, 2003, 98, 798-804.
2. Vasen, H.F.; Gruis, N.A.; Frants, R.R.; van Der Velden, P.A.; Hille, E.T.; Bergman, W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer, 2000, 87, 809-811.
3. Zuo, L.; Weger, J.; Yang, Q.; Goldstein, A.M.; Tucker, M.A.; Walker, G.J.; Hayward, N.; Dracopoli, N.C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet., 1996, 12, 97-99.
4. Hayward, N.K. Genetics of melanoma predisposition. Oncogene, 2003, 22, 3053-3062.
5. Ghiorzo, P.; Villaggio, B.; Sementa, A.R.; Hansson, J.; Platz, A.; Nicolo, G.; Spina, B.; Canepa, M.; Palmer, J.M.; Hayward, N.K.; Bianchi-Scarra, G. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum. Pathol., 2004, 35, 25-33.
6. Terando, A.; Sabel, M.S.; Sondak, V.K. Melanoma: adjuvant therapy and other treatment options. Curr. Treat. Options Oncol., 2003, 4, 187-199.
7. Sabel, M.S.; Sondak, V.K. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist, 2003, 8, 451-458.
8. Anderson, C.M.; Buzaid, A.C.; Legha, S.S. Systemic treatments for advanced cutaneous melanoma. Oncology, 1995, 9, 1149-1158.
9. Wagner, J.D.; Gordon, M.S.; Chuang, T.Y.; Coleman, J.J., 3rd. Current therapy of cutaneous melanoma. Plast. Reconstr. Surg., 2000, 105, 1774-1799, quiz 1800-1771.
10. Chapman, P.B.; Einhorn, L.H.; Meyers, M.L.; Saxman, S.; Destro, A.N.; Panageas, K.S.; Begg, C.B.; Agarwala, S.S.; Schuchter, L.M.; Ernstoff, M.S.; Houghton, A.N.; Kirkwood, J.M. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol., 1999, 17, 2745-2751.
11. Mays, S.R.; Nelson, B.R. Current therapy of cutaneous melanoma. Cutis, 1999, 63, 293-298.
12. Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; Rosenberg, S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 1999, 17, 2105-2116.
13. Atkins, M.B.; Kunkel, L.; Sznol, M.; Rosenberg, S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J., 2000, 6 (Suppl. 1), S11-14.
14. Rosenberg, S.A.; Yang, J.C.; Topalian, S.L.; Schwartzentruber, D.J.; Weber, J.S.; Parkinson, D.R.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 1994, 271, 907-913.
15. Curtin, J.A.; Fridlyand, J.; Kageshita, T.; Patel, H.N.; Busam, K.J.; Kutzner, H.; Cho, K.H.; Aiba, S.; Brocker, E.B.; LeBoit, P.E.; Pinkel, D.; Bastian, B.C. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med., 2005, 353, 2135-2147.
16. Wong, C.W.; Fan, Y.S.; Chan, T.L.; Chan, A.S.; Ho, L.C.; Ma, T.K.; Yuen, S.T.; Leung, S.Y. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J. Clin. Pathol., 2005, 58, 640-644.
17. Poynter, J.N.; Elder, J.T.; Fullen, D.R.; Nair, R.P.; Soengas, M.S.; Johnson, T.M.; Redman, B.; Thomas, N.E.; Gruber, S.B. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res., 2006, 16, 267-273.
18. Saldanha, G.; Potter, L.; Daforno, P.; Pringle, J.H. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin. Cancer Res., 2006, 12, 4499-4505.
19. Viros, A.; Fridlyand, J.; Bauer, J.; Lasithiotakis, K.; Garbe, C.; Pinkel, D.; Bastian, B.C. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med., 2008, 5, e120.
20. Yazdi, A.S.; Palmedo, G.; Flaig, M.J.; Puchta, U.; Reckwerth, A.; Rutten, A.; Mentzel, T.; Hugel, H.; Hantschke, M.; Schmid-Wendtner, M.H.; Kutzner, H.; Sander, C.A. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol., 2003, 121, 1160-1162.
21. Pollock, P.M.; Harper, U.L.; Hansen, K.S.; Yudt, L.M.; Stark, M.; Robbins, C.M.; Moses, T.Y.; Hostetter, G.; Wagner, U.; Kakareka, J.; Salem, G.; Pohida, T.; Heenan, P.; Duray, P.; Kallioniemi, O.; Hayward, N.K.; Trent, J.M.; Meltzer, P.S. High frequency of BRAF mutations in nevi. Nat. Genet., 2003, 33, 19-20.
22. James, M.R.; Dumeni, T.; Stark, M.S.; Duffy, D.L.; Montgomery, G.W.; Martin, N.G.; Hayward, N.K. Rapid screening of 4000 individuals for germ-line variations in the BRAF gene. Clin. Chem., 2006, 52, 1675-1678.
23. Demunter, A.; Stas, M.; Degreef, H.; De Wolf-Peeters, C.; van den Oord, J.J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol., 2001, 117, 1483-1489.
24. Montagut, C.; Sharma, S.V.; Shioda, T.; McDermott, U.; Ulman, M.; Ulkus, L.E.; Dias-Santagata, D.; Stubbs, H.; Lee, D.Y.; Singh, A.; Drew, L.; Haber, D.A.; Settleman, J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res., 2008, 68, 4853-4861.
25. Bauer, J.; Curtin, J.A.; Pinkel, D.; Bastian, B.C. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Invest. Dermatol., 2007, 127, 179-182.
26. Curtin, J.A.; Busam, K.; Pinkel, D.; Bastian, B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol., 2006, 24, 4340-4346.
27. Beadling, C.; Jacobson-Dunlop, E.; Hodi, F.S.; Le, C.; Warrick, A.; Patterson, J.; Town, A.; Harlow, A.; Cruz, F., 3rd.; Azar, S.; Rubin, B.P.; Muller, S.; West, R.; Heinrich, M.C.; Corless, C.L. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res., 2008, 14, 6821-6828.
28. Jiang, X.; Zhou, J.; Yuen, N.K.; Corless, C.L.; Heinrich, M.C.; Fletcher, J.A.; Demetri, G.D.; Widlund, H.R.; Fisher, D.E.; Hodi, F.S. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res., 2008, 14, 7726-7732.
29. Lutzky, J.; Bauer, J.; Bastian, B.C. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res., 2008, 21, 492-493.
30. Jilaveanu, L.; Zito, C.; Lee, S.J.; Nathanson, K.L.; Camp, R.L.; Rimm, D.L.; Flaherty, K.T.; Kluger, H.M. Expression of sorafenib targets in melanoma patients treated with Carboplatin, Paclitaxel and sorafenib. Clin. Cancer Res., 2009, 15, 1076-1085.
31. Quintas-Cardama, A.; Lazar, A.J.; Woodman, S.E.; Kim, K.; Ross, M.; Hwu, P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat. Clin. Pract. Oncol., 2008, 5, 737-740.
32. Rakosy, Z.; Vizkeleti, L.; Ecsedi, S.; Voko, Z.; Begany, A.; Barok, M.; Krekk, Z.; Gallai, M.; Szentirmay, Z.; Adany, R.; Balazs, M. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int. J. Cancer, 2007, 121, 1729-1737.
33. Shen, S.S.; Zhang, P.S.; Eton, O.; Prieto, V.G. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J. Cutan. Pathol., 2003, 30, 539-547.
34. Bastian, B.C.; Olshen, A.B.; LeBoit, P.E.; Pinkel, D. Classifying melanocytic tumors based on DNA copy number changes. Am. J. Pathol., 2003, 163, 1765-1770.
35. Bauer, J.; Bastian, B. Genomic analysis of melanocytic neoplasia. Adv. Dermatol., 2005, 21, 81-99.
36. Riker, A.I.; Enkemann, S.A.; Fodstad, O.; Liu, S.; Ren, S.; Morris, C.; Xi, Y.; Howell, P.; Metge, B.; Samant, R.S.; Shevde, L.A.; Li, W.; Eschrich, S.; Daud, A.; Ju, J.; Matta, J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genomics, 2008, 1, 13.
37. Gartside, M.G.; Chen, H.; Ibrahimi, O.A.; Byron, S.A.; Curtis, A.V.; Wellens, C.L.; Bengston, A.; Yudt, L.M.; Eliseenkova, A.V.; Ma, J.; Curtin, J.A.; Hyder, P.; Harper, U.L.; Riedesel, E.; Mann, G.J.; Trent, J.M.; Bastian, B.C.; Meltzer, P.S.; Mohammadi, M.; Pollock, P.M. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res., 2009, 7, 41-54.
38. Daniotti, M.; Oggionni, M.; Ranzani, T.; Vallacchi, V.; Campi, V.; Di Stasi, D.; Torre, G.D.; Perrone, F.; Luoni, C.; Suardi, S.; Frattini, M.; Pilotti, S.; Anichini, A.; Tragni, G.; Parmiani, G.; Pierotti, M.A.; Rodolfo, M. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene, 2004.
39. Abdel-Rahman, M.H.; Yang, Y.; Zhou, X.P.; Craig, E.L.; Davidorf, F.H.; Eng, C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J. Clin. Oncol., 2006, 24, 288-295.
40. Slipicevic, A.; Holm, R.; Nguyen, M.T.; Bohler, P.J.; Davidson, B.; Florenes, V.A. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am. J. Clin. Pathol., 2005, 124, 528-536.
41. Mirmohammadsadegh, A.; Marini, A.; Nambiar, S.; Hassan, M.; Tannapfel, A.; Ruzicka, T.; Hengge, U.R. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res., 2006, 66, 6546-6552.
42. Goel, V.K.; Lazar, A.J.; Warneke, C.L.; Redston, M.S.; Haluska, F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol., 2006, 126, 154-160.
43. Wu, H.; Goel, V.; Haluska, F.G. PTEN signaling pathways in melanoma. Oncogene, 2003, 22, 3113-3122.
44. Davies, M.A.; Stemke-Hale, K.; Tellez, C.; Calderone, T.L.; Deng, W.; Prieto, V.G.; Lazar, A.J.; Gershenwald, J.E.; Mills, G.B. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer, 2008, 99, 1265-1268.
45. Stahl, J.M.; Sharma, A.; Cheung, M.; Zimmerman, M.; Cheng, J.Q.; Bosenberg, M.W.; Kester, M.; Sandirasegarane, L.; Robertson, G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res., 2004, 64, 7002-7010.
46. Govindarajan, B.; Sligh, J.E.; Vincent, B.J.; Li, M.; Canter, J.A.; Nickoloff, B.J.; Rodenburg, R.J.; Smeitink, J.A.; Oberley, L.; Zhang, Y.; Slingerland, J.; Arnold, R.S.; Lambeth, J.D.; Cohen, C.; Hilenski, L.; Griendling, K.; Martinez-Diez, M.; Cuezva, J.M.; Arbiser, J.L. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest., 2007, 117, 719-729.
47. Akslen, L.A.; Puntervoll, H.; Bachmann, I.M.; Straume, O.; Vuhahula, E.; Kumar, R.; Molven, A. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res., 2008, 18, 29-35.
48. Hacker, E.; Hayward, N.K. Germline MC1R variants and BRAF mutant melanoma. J. Invest. Dermatol., 2008, 128, 2354-2356.
49. Bishop, D.T.; Demenais, F.; Goldstein, A.M.; Bergman, W.; Bishop, J.N.; Bressac-de Paillerets, B.; Chompret, A.; Ghiorzo, P.; Gruis, N.; Hansson, J.; Harland, M.; Hayward, N.; Holland, E.A.; Mann, G.J.; Mantelli, M.; Nancarrow, D.; Platz, A.; Tucker, M.A. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl. Cancer Inst., 2002, 94, 894-903.
50. Brown, K.M.; Macgregor, S.; Montgomery, G.W.; Craig, D.W.; Zhao, Z.Z.; Iyadurai, K.; Henders, A.K.; Homer, N.; Campbell, M.J.; Stark, M.; Thomas, S.; Schmid, H.; Holland, E.A.; Gillanders, E.M.; Duffy, D.L.; Maskiell, J.A.; Jetann, J.; Ferguson, M.; Stephan, D.A.; Cust, A.E.; Whiteman, D.; Green, A.; Olsson, H.; Puig, S.; Ghiorzo, P.; Hansson, J.; Demenais, F.; Goldstein, A.M.; Gruis, N.A.; Elder, D.E.; Bishop, J.N.; Kefford, R.F.; Giles, G.G.; Armstrong, B.K.; Aitken, J.F.; Hopper, J.L.; Martin, N.G.; Trent, J.M.; Mann, G.J.; Hayward, N.K. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet., 2008, 40, 838-840.
51. Flaherty, K.T.; Schiller, J.; Schuchter, L.M.; Liu, G.; Tuveson, D.A.; Redlinger, M.; Lathia, C.; Xia, C.; Petrenciuc, O.; Hingorani, S.R.; Jacobetz, M.A.; Van Belle, P.A.; Elder, D.; Brose, M.S.; Weber, B.L.; Albertini, M.R.; O'Dwyer, P.J. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res., 2008, 14, 4836-4842.
52. Kim, K.B.; Eton, O.; Davis, D.W.; Frazier, M.L.; McConkey, D.J.; Diwan, A.H.; Papadopoulos, N.E.; Bedikian, A.Y.; Camacho, L.H.; Ross, M.I.; Cormier, J.N.; Gershenwald, J.E.; Lee, J.E.; Mansfield, P.F.; Billings, L.A.; Ng, C.S.; Charnsangavej, C.; Bar-Eli, M.; Johnson, M.M.; Murgo, A.J.; Prieto, V.G. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer, 2008, 99, 734-740.
53. van der Velden, P.A.; Metzelaar-Blok, J.A.; Bergman, W.; Monique, H.; Hurks, H.; Frants, R.R.; Gruis, N.A.; Jager, M.J. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res., 2001, 61, 5303-5306.
54. Worm, J.; Christensen, C.; Gronbaek, K.; Tulchinsky, E.; Guldberg, P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene, 2004, 23, 5215-5226.
55. Spugnardi, M.; Tommasi, S.; Dammann, R.; Pfeifer, G.P.; Hoon, D.S. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res., 2003, 63, 1639-1643.
56. Rastetter, M.; Schagdarsurengin, U.; Lahtz, C.; Fiedler, E.; Marsch, W.; Dammann, R.; Helmbold, P. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol. Histopathol., 2007, 22, 1005-1015.
57. Liu, L.; Gerson, S.L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res., 2006, 12, 328-331.
58. Alonso, S.R.; Ortiz, P.; Pollan, M.; Perez-Gomez, B.; Sanchez, L.; Acuna, M.J.; Pajares, R.; Martinez-Tello, F.J.; Hortelano, C.M.; Piris, M.A.; Rodriguez-Peralto, J.L. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol., 2004, 164, 193-203.
59. Haqq, C.; Nosrati, M.; Sudilovsky, D.; Crothers, J.; Khodabakhsh, D.; Pulliam, B.L.; Federman, S.; Miller, J.R., 3rd.; Allen, R.E.; Singer, M.I.; Leong, S.P.; Ljung, B.M.; Sagebiel, R.W.; Kashani-Sabet, M. The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. USA, 2005, 102, 6092-6097.
60. Hoek, K.S. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res., 2007, 20, 466-484.
61. Jaeger, J.; Koczan, D.; Thiesen, H.J.; Ibrahim, S.M.; Gross, G.; Spang, R.; Kunz, M. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res., 2007, 13, 806-815.
62. Mandruzzato, S.; Callegaro, A.; Turcatel, G.; Francescato, S.; Montesco, M.C.; Chiarion-Sileni, V.; Mocellin, S.; Rossi, C.R.; Bicciato, S.; Wang, E.; Marincola, F.M.; Zanovello, P. A gene expression signature associated with survival in metastatic melanoma. J. Transl. Med., 2006, 4, 50.
63. Nambiar, S.; Mirmohammadsadegh, A.; Hassan, M.; Mota, R.; Marini, A.; Alaoui, A.; Tannapfel, A.; Hegemann, J.H.; Hengge, U.R. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. Carcinogenesis, 2007, 28, 2501-2510.
64. Ryu, B.; Kim, D.S.; Deluca, A.M.; Alani, R.M. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE, 2007, 2, e594.
65. Seykora, J.T.; Jih, D.; Elenitsas, R.; Horng, W.H.; Elder, D.E. Gene expression profiling of melanocytic lesions. Am. J. Dermatopathol., 2003, 25, 6-11.
66. Ivan, D.; Diwan, A.H.; Esteva, F.J.; Prieto, V.G. Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod. Pathol., 2004, 17, 811-818.
67. Woenckhaus, C.; Fenic, I.; Giebel, J.; Hauser, S.; Failing, K.; Woenckhaus, J.; Dittberner, T.; Poetsch, M. Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression. Virchows Arch., 2004, 445, 491-497.
68. Suzuki, N.; Onda, T.; Yamamoto, N.; Katakura, A.; Mizoe, J.E.; Shibahara, T. Mutation of the p16/CDKN2 gene and loss of heterozygosity in malignant mucosal melanoma and adenoid cystic carcinoma of the head and neck. Int. J. Oncol., 2007, 31, 1061-1067.
69. Pavey, S.J.; Cummings, M.C.; Whiteman, D.C.; Castellano, M.; Walsh, M.D.; Gabrielli, B.G.; Green, A.; Hayward, N.K. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res., 2002, 12, 539-547.
70. Demirkan, N.C.; Kesen, Z.; Akdag, B.; Larue, L.; Delmas, V. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions. Clin. Exp. Dermatol., 2007, 32, 733-739.
71. Wang, Y.; Ji, P.; Liu, J.; Broaddus, R.R.; Xue, F.; Zhang, W. Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy. Mol. Cancer, 2009, 8, 8.
72. Song, M.S.; Chang, J.S.; Song, S.J.; Yang, T.H.; Lee, H.; Lim, D.S. The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles. J. Biol. Chem., 2005, 280, 3920-3927.
73. Whitehurst, A.W.; Ram, R.; Shivakumar, L.; Gao, B.; Minna, J.D.; White, M.A. The RASSF1A tumor suppressor restrains anaphase-promoting complex/ cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells. Mol. Cell Biol., 2008, 28, 3190-3197.
74. Oh, H.J.; Lee, K.K.; Song, S.J.; Jin, M.S.; Song, M.S.; Lee, J.H.; Im, C.R.; Lee, J.O.; Yonehara, S.; Lim, D.S. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res., 2006, 66, 2562-2569.
75. Rother, J.; Bailey, J.; Alvarado, G.; Prieto, V.; Lazar, A.; Jones, D.; W-J, H. Molecular dissection of the RAS/RAF/MAPK pathway in primary and metastatic melanoma. J. Clin. Oncol., 2006, 24, 8050.
76. Rong, R.; Jiang, L.Y.; Sheikh, M.S.; Huang, Y. Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene, 2007, 26, 7700-7708.
77. Haruta, M.; Matsumoto, Y.; Izumi, H.; Watanabe, N.; Fukuzawa, M.; Matsuura, S.; Kaneko, Y. Combined BubR1 protein down-regulation and RASSF1A hypermethylation in Wilms tumors with diverse cytogenetic changes. Mol. Carcinog., 2008, 47: 660-666.
78. Song, M.S.; Song, S.J.; Ayad, N.G.; Chang, J.S.; Lee, J.H.; Hong, H.K.; Lee, H.; Choi, N.; Kim, J.; Kim, H.; Kim, J.W.; Choi, E.J.; Kirschner, M.W.; Lim, D.S. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat. Cell Biol., 2004, 6, 129-137.
79. Xie, T.; Nguyen, T.; Hupe, M.; Wei, M.L. Multidrug resistance decreases with mutations of melanosomal regulatory genes. Cancer Res., 2009, 69, 992-999.
80. Chen, K.G.; Valencia, J.C.; Lai, B.; Zhang, G.; Paterson, J.K.; Rouzaud, F.; Berens, W.; Wincovitch, S.M.; Garfield, S.H.; Leapman, R.D.; Hearing, V.J.; Gottesman, M.M. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc. Natl. Acad. Sci. USA, 2006, 103, 9903-9907.
81. Augustine, C.K.; Yoo, J.S.; Potti, A.; Yoshimoto, Y.; Zipfel, P.A.; Friedman, H.S.; Nevins, J.R.; Ali-Osman, F.; Tyler, D.S. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin. Cancer Res., 2009, 15, 502-510.
82. Gao, K.; Lockwood, W.W.; Li, J.; Lam, W.; Li, G. Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells. Int. J. Oncol., 2008, 32, 1343-1349.
83. Da Forno, P.D.; Pringle, J.H.; Hutchinson, P.; Osborn, J.; Huang, Q.; Potter, L.; Hancox, R.A.; Fletcher, A.; Saldanha, G.S. WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res., 2008, 14, 5825-5832.